RBM-007 strongly suggests that it could be a new drug for cartilage dysplasia!
We would like to introduce the clinical trials conducted by our company. The project concerning achondroplasia received support from the Japan Agency for Medical Research and Development (AMED) and began a Phase 1 trial in July 2020 at a domestic clinical trial facility to investigate the safety, tolerability, and pharmacokinetics of RBM-007, which was conducted until May 2021. Regarding the Phase 2 trial of this project, it has been adopted as a pre-commercialization support project for orphan drugs by AMED for three years starting from the fiscal year 2021. [Main Trials] ■ Phase 1 Clinical Trial ■ Early Phase 2 Observational Trial ■ Early Phase 2 Clinical Trial ■ Early Phase 2 Long-term Clinical Trial *For more details, please refer to the PDF materials or feel free to contact us.
Inquire About This Product
basic information
For more details, please refer to the PDF document or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
For more details, please refer to the PDF document or feel free to contact us.
catalog（1）
Download All Catalogs
Company information
Our company is engaged in drug discovery business utilizing the drug discovery technology "RiboART System" to develop various new drugs that are not limited to specific diseases or target proteins. This drug discovery business consists of two components: in-house drug discovery and collaborative research with other pharmaceutical companies. For some drug candidates, we will conduct clinical trials in-house and, after obtaining Proof of Concept (POC), we will license them out to pharmaceutical companies.
![[Research Material] Global Market for the Treatment of Diabetic Peripheral Neuropathy](https://image.mono.ipros.com/public/product/image/292/2001470444/IPROS74136983917863278804.jpeg?w=280&h=280)
